Table 3.
Univariate Results of Factors of Interest with Musculoskeletal Symptoms.
| Characteristic | Odds Ratio (95% CI) | P-value |
|---|---|---|
| Age at Diagnosis, per 10 years | 0.97 (0.94–1.00) | 0.069 |
| Body Mass Index, kg/m2 | 1.00 (0.99–1.00) | 0.002 |
| Site of Origin – ovarian vs. uterine | 1.01 (0.94–1.10) | 0.767 |
| Histology – carcinoma vs. other | 0.90 (0.80–1.03) | 0.120 |
| Stage | 0.358 | |
| II vs. I | 1.03 (0.94–1.14) | 0.547 |
| III vs. I | 1.00 (0.90–1.10) | 0.931 |
| IV vs. I | 1.10 (0.96–1.27) | 0.152 |
| Prior Radiation Therapy – yes vs. no | 0.91 (0.85–0.98) | 0.010 |
| Number of Prior Lines of Chemotherapy | 1.00 (0.98–1.02) | 0.947 |
| Aromatase Inhibitor | 0.012 | |
| Anastrozole vs. Exemestane | 0.82 (0.70–0.95) | 0.010 |
| Letrozole vs. Exemestane | 0.79 (0.67–0.92) | 0.003 |
| Patient Previously on a SERM – yes vs.no | 1.01 (0.90–1.14) | 0.814 |
| AIMSS-like Symptoms Prior to Start Date – yes vs. no | 1.01 (0.93–1.11) | 0.789 |
| Medications During AI Use | ||
| Duloxetine: yes vs. no | 1.06 (0.86–1.32) | 0.577 |
| Other SNRI (Venlafaxine): yes vs. no | 0.98 (0.79–1.21) | 0.852 |
| SSRI: yes vs. no | 0.86 (0.81–0.92) | <0.001 |
| NSAIDS: yes vs. no | 1.03 (0.95–1.10) | 0.51 |
| Narcotics: yes vs. no | 1.00 (0.94–1.08) | 0.894 |
| Gabapentin: yes vs. no | 0.86 (0.82–0.91) | <0.001 |
| Measurable Disease at AI Initiation – yes vs. no | 0.90 (0.83–0.98) | 0.019 |
Odds ratio is calculated using generalized estimating equations approach to explore associations between musculoskeletal symptoms and factors of interest.
SERM = selective estrogen receptor modulator; AI = aromatase inhibitor; AIMSS = aromatase inhibitor musculoskeletal syndrome; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; NSAID = nonsteroidal anti-inflammatory drug.